| Literature DB >> 29197403 |
Peter Tugwell1,2,3, Jennifer Petkovic4, Vivian Welch4, Jennifer Vincent4, Zulfiqar A Bhutta5, Rachel Churchill6, Don deSavigny7, Lawrence Mbuagbaw8, Tomas Pantoja9.
Abstract
BACKGROUND: A focus on equity in health can be seen in many global development goals and reports, research and international declarations. With the development of a relevant framework and methods, the Campbell and Cochrane Equity Methods Group has encouraged the application of an 'equity lens' to systematic reviews, and many organizations publish reviews intended to address health equity. The purpose of the Evidence for Equity (E4E) project was to conduct a priority-setting exercise and apply an equity lens by developing a knowledge translation product comprising summaries of systematic reviews from the Cochrane Library. E4E translates evidence from systematic reviews into 'friendly front end' summaries for policy makers.Entities:
Keywords: Equity; Priority setting; Systematic reviews
Mesh:
Year: 2017 PMID: 29197403 PMCID: PMC5712153 DOI: 10.1186/s12939-017-0697-5
Source DB: PubMed Journal: Int J Equity Health ISSN: 1475-9276
Characteristics of Participants in all Stakeholder Panels
| N (%) | |
|---|---|
| Total | 32 |
| Male | 26 (81.25) |
| Female | 6 (18.75) |
| Country | |
| High-income | 21 (65.6) |
| Low- and middle-income | 11 (34.4) |
| Australia | 1 (3.1) |
| Argentina | 1 (3.1) |
| Cameroon | 2 (6.25) |
| Canada | 6 (18.8) |
| Chile | 1 (3.1) |
| India | 1 (3.1) |
| Italy | 1 (3.1) |
| Kenya | 2 (6.25) |
| Lebanon | 1 (3.1) |
| Pakistan | 1 (3.1) |
| Peru | 1 (3.1) |
| South Africa | 3 (9.4) |
| Switzerland | 3 (9.4) |
| US | 5 (15.63) |
| UK | 3 (9.4) |
| Role | |
| Clinician | 12 (37.5) |
| Policy | 22 (68.8) |
| Researcher | 30 (93.8) |
Note: percentages do not add to 100 since stakeholders could have multiple roles
Diabetes/obesity top 10 interventions
| Intervention | Outcome | Feasibilitya | Deliverabilityb | Universalityc | Effect on Equityd | Overall Rating (%) | |
|---|---|---|---|---|---|---|---|
| 1 | Sulphonylureas versus insulin | All-cause mortality; best-worst case scenario | Range: 2–4 Total: 75 Rank: 3 | Range: 2–4 Total: 75 Rank: 1 | Range: 2–4 Total: 75 Rank: 5 | Range: 2–4 Total: 70.83 Rank:7 | 76.67 Rank: 1 |
| 2 | metformin vs sulphonylureas or insulin. | all cause mortality | Range: 2–4 Total: 87.5 Rank: 1 | Range: 2–4 Total: 66.67 Rank: 5 | Range: 2–4 Total: 75 Rank: 5 | Range: 2–4 Total: 70.83 Rank: 7 | 75 Rank: 2 |
| 3 | ACEi versus placebo/no treatment | All cause mortality | Range: 2–4 Total: 80 Rank: 2 | Range: 2–4 Total: 75 Rank:1 | Range: 3–4 Total: 85 Rank: 1 | Range: 2–3 Total: 70 Rank: 8 | 71.15 Rank: 3 |
| 4 | Low salt vs high salt diet | Systolic BP | Range: 1–3 Total: 62.5 Rank: 9 | Range: 1–4 Total: 71.88 Rank: 2 | Range: 2–3 Total: 59.38 Rank: 14 | Range: 2–4 Total: 71.88 Rank: 5 | 77.5 Rank: 4 |
| 5 | Exercise vs no exercise | Glycated haemoglobin (%) | Range: 1–3 Total: 62.5 Rank: 9 | Range: 2–4 Total: 71.88 Rank: 2 | Range: 2–3 Total: 71.88 Rank: 6 | Range: 2–3 Total: 68.75 Rank: 9 | 73 Rank: 5 |
| 6 | Group-based diabetes education programme versus individual routine treatment | reduction in diabetes medication | Range: 1–4 Total: 53.13 Rank: 15 | Range: 2–4 Total: 68.75 Rank: 4 | Range: 2–3 Total: 65.63 Rank: 9 | Range: 2–4 Total: 81.25 Rank: 1 | 73 Rank: 5 |
| 7 | Effects of intensive versus brief education in high risk patient samples | Foot ulcer incidence (1-year follow-up) | Range: 1–3 Total: 50 Rank: 16 | Range: 2–4 Total: 65.63 Rank: 6 | Range: 2–4 Total: 65.63 Rank: 9 | Range: 2–4 Total: 78.13 Rank: 3 | 71 Rank: 6 |
| 8 | Tight-moderate versus loose glycaemic control | Pre-eclampsia | Range: 0–3 Total: 46.43 Rank: 18 | Range: 0–3 Total: 50 Rank: 19 | Range: 0–3 Total: 53.57 Rank: 18 | Range: 0–3 Total: 53.57 Rank: 18 | 70.31 Rank: 7 |
| Very tight versus tight-moderate glycaemic control | Maternal hospitalisation (days) | ||||||
| Tight versus moderate glycaemic control | Maternal hypoglycaemia in first half of pregnancy | ||||||
| 9 | low glycaemic index (LGI) vs high glycaemic index | large-for-gestational age | Range: 2–4 Total: 68.75 Rank: 5 | Range: 2–4 Total: 75 Rank: 1 | Range: 2–4 Total: 78.13 Rank: 4 | Range: 2–4 Total: 78.13 Rank: 3 | 67 Rank: 8 |
| 10 | ACEi versus placebo/no treatment | Systolic BP | Range: 2–4 Total: 75 Rank: 3 | Range: 2–4 Total: 68.75 Rank: 4 | Range: 2–4 Total: 75 Rank: 5 | Range: 2–3 Total: 68.75 Rank: 9 | 65.38 Rank: 9 |
aIs there sufficient capacity to implement the intervention? Is it feasible to provide required training to staff? Rankings are 0 to 4. 4 = optimal (easier to implement), 0 = more difficult
bConsider the level of difficulty with intervention delivery, the infrastructure required (human resources, facilities, etc.). Consider the resources available and whether the intervention is affordable. Rank 0–4, 4 = optimal (easier/fewer health system effects), 0 = more difficult/greater health system effects,
cIs the intervention relevant to most countries? Rankings are 0 to 4. 4 = Optimal (more generalizable/population-based, 0 = less generalizable/specific population
dDoes the distribution of the disease burden affect mainly the disadvantaged? Are the disadvantaged most likely to benefit from the intervention? Will the intervention improve equity in disease burden distribution long-term? Rankings are 0 to 4. 4 = Optimal (more generalizable/population-based, 0 = less generalizable/specific population
| Take Home Messages |
| 1. For policy makers and program managers in high- or low-/middle-income countries who want to make evidence-based decisions on equity-focused interventions, it is challenging to find evidence on interventions that are effective. |